title: HER2 breast cancer therapies: a review.
abstract: Amplification of the HER2 gene and/or overexpression of its protein product have been found in up to 25% to 30% of human breast cancers and have been shown to be associated with poorer outcomes compared to 'HER2 normal' breast cancer. Research has focused on developing therapies directed to the HER2 receptor and its pathway. These include the monoclonal antibody trastuzumab, which has improved outcomes when used in patients with both advanced and early breast cancer. Lapatinib is a small-molecule tyrosine kinase inhibitor which has demonstrated activity in advanced breast cancer and is currently being evaluated in early stage disease. We discuss the therapeutic rationale and clinical trial experience with these agents. Other novel and emerging strategies targeting the HER2 receptor and its pathway are also discussed. These strategies include novel HER2 antibodies and small-molecule inhibitors, antibody-drug conjugates, agents targeting downstream components of the HER2 signaling pathway, and heat shock protein 90 (HSP90) inhibitors.
authors.affiliation: Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. murpphyc@mskcc.org
authors.forename: Conleth G
authors.initials: CG
authors.lastname: Murphy
authors.forename: Shanu
authors.initials: S
authors.lastname: Modi
references.citation: J Clin Oncol. 2001 May 15;19(10):2587-95
references.pmid: 11352950
references.citation: J Clin Oncol. 2005 Aug 10;23(23):5305-13
references.pmid: 15955900
references.citation: N Engl J Med. 2005 Oct 20;353(16):1673-84
references.pmid: 16236738
references.citation: J Clin Oncol. 1999 Sep;17(9):2639-48
references.pmid: 10561337
references.citation: Ann Oncol. 2008 Jun;19(6):1068-74
references.pmid: 18283035
references.citation: J Clin Oncol. 1996 Mar;14(3):737-44
references.pmid: 8622019
references.citation: Clin Cancer Res. 2007 Mar 15;13(6):1769-74
references.pmid: 17363531
references.citation: J Natl Cancer Inst. 2004 May 19;96(10):759-69
references.pmid: 15150304
references.citation: Cancer Res. 2006 Feb 1;66(3):1630-9
references.pmid: 16452222
references.citation: Ann Oncol. 2009 Jun;20(6):1026-31
references.pmid: 19179558
references.citation: Science. 1987 Jan 9;235(4785):177-82
references.pmid: 3798106
references.citation: Cancer Res. 1990 Mar 1;50(5):1550-8
references.pmid: 1689212
references.citation: Adv Exp Med Biol. 2003;532:253-68
references.pmid: 12908564
references.citation: J Clin Oncol. 2005 Nov 1;23(31):7811-9
references.pmid: 16258083
references.citation: Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14536-41
references.pmid: 8962087
references.citation: J Clin Oncol. 2007 Aug 10;25(23):3525-33
references.pmid: 17687157
references.citation: J Natl Cancer Inst. 2007 Apr 18;99(8):628-38
references.pmid: 17440164
references.citation: J Clin Oncol. 1993 Oct;11(10):1936-42
references.pmid: 8105035
references.citation: Int J Oncol. 2007 Oct;31(4):769-76
references.pmid: 17786307
references.citation: Cancer Cell. 2007 Oct;12(4):395-402
references.pmid: 17936563
references.citation: Cancer Res. 2004 Jun 1;64(11):3981-6
references.pmid: 15173011
references.citation: Curr Top Med Chem. 2006;6(11):1205-14
references.pmid: 16842157
references.citation: N Engl J Med. 1987 Oct 8;317(15):955-7
references.pmid: 3627214
references.citation: Clin Breast Cancer. 2004 Jun;5(2):142-7
references.pmid: 15245619
references.citation: Clin Cancer Res. 2007 Aug 15;13(16):4909-19
references.pmid: 17699871
references.citation: Clin Cancer Res. 2002 May;8(5):986-93
references.pmid: 12006510
references.citation: Clin Cancer Res. 2007 Mar 15;13(6):1775-82
references.pmid: 17363532
references.citation: J Clin Oncol. 2003 Aug 1;21(15):2889-95
references.pmid: 12885806
references.citation: J Clin Oncol. 1989 Aug;7(8):1120-8
references.pmid: 2569032
references.citation: Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6087-93
references.pmid: 17062684
references.citation: Oncogene. 2004 Jan 22;23(3):646-53
references.pmid: 14737100
references.citation: Cardiovasc Toxicol. 2007;7(2):114-21
references.pmid: 17652815
references.citation: Lancet. 2007 Jan 6;369(9555):29-36
references.pmid: 17208639
references.citation: Clin Cancer Res. 2005 May 1;11(9):3385-91
references.pmid: 15867239
references.citation: Science. 1989 May 12;244(4905):707-12
references.pmid: 2470152
references.citation: J Natl Cancer Inst. 2008 Aug 6;100(15):1092-103
references.pmid: 18664652
references.citation: Cancer Res. 2008 Nov 15;68(22):9280-90
references.pmid: 19010901
references.citation: Cancer Cell. 2004 Apr;5(4):317-28
references.pmid: 15093539
references.citation: Oncogene. 2005 Sep 15;24(41):6213-21
references.pmid: 16091755
references.citation: Oncogene. 2002 Feb 14;21(8):1159-66
references.pmid: 11850835
references.citation: J Clin Oncol. 1998 Aug;16(8):2659-71
references.pmid: 9704716
references.citation: J Clin Oncol. 2005 Feb 20;23(6):1078-87
references.pmid: 15718306
references.citation: Clin Cancer Res. 2001 Dec;7(12 Suppl):4436s-4442s; discussion 4411s-4412s
references.pmid: 11916237
references.citation: J Clin Oncol. 2005 Nov 1;23(31):7820-6
references.pmid: 16258084
references.citation: Breast Cancer Res. 2006;8(6):215
references.pmid: 17096862
references.citation: Mol Cancer Ther. 2002 Jul;1(9):707-17
references.pmid: 12479367
references.citation: J Clin Oncol. 2002 Feb 1;20(3):719-26
references.pmid: 11821453
references.citation: J Clin Oncol. 2007 Dec 1;25(34):5410-7
references.pmid: 18048823
references.citation: J Clin Oncol. 2005 Jul 1;23(19):4265-74
references.pmid: 15911866
references.citation: Expert Opin Biol Ther. 2002 Jan;2(1):3-24
references.pmid: 11772336
references.citation: Cancer Chemother Pharmacol. 2008 Mar;61(3):509-14
references.pmid: 17516068
references.citation: Invest New Drugs. 2005 Jan;23(1):39-49
references.pmid: 15528979
references.citation: Immunol Lett. 2008 Mar 15;116(2):126-40
references.pmid: 18201769
references.citation: N Engl J Med. 2006 Feb 23;354(8):809-20
references.pmid: 16495393
references.citation: Proc Natl Acad Sci U S A. 1992 May 15;89(10):4285-9
references.pmid: 1350088
references.citation: Oncogene. 2002 Sep 12;21(41):6255-63
references.pmid: 12214266
references.citation: Clin Breast Cancer. 2008 Oct;8(5):453-6
references.pmid: 18952561
references.citation: Breast Cancer Res Treat. 2008 Dec;112(3):533-43
references.pmid: 18188694
references.citation: J Clin Oncol. 2007 Aug 1;25(22):3246-50
references.pmid: 17577021
references.citation: N Engl J Med. 2006 Dec 28;355(26):2733-43
references.pmid: 17192538
references.citation: Exp Hematol. 1999 Oct;27(10):1533-41
references.pmid: 10517495
references.citation: J Clin Oncol. 2007 Sep 1;25(25):3853-8
references.pmid: 17679724
references.citation: J Clin Oncol. 2002 Apr 1;20(7):1800-8
references.pmid: 11919237
references.citation: Mol Cancer Ther. 2001 Dec;1(2):85-94
references.pmid: 12467226
references.citation: Mol Biol Cell. 2004 Dec;15(12):5268-82
references.pmid: 15385631
references.citation: Semin Oncol. 2001 Oct;28(5 Suppl 16):4-11
references.pmid: 11706390
references.citation: J Clin Oncol. 2005 Mar 20;23(9):1885-93
references.pmid: 15774780
references.citation: N Engl J Med. 2005 Oct 20;353(16):1659-72
references.pmid: 16236737
references.citation: Nature. 2002 Mar 21;416(6878):279-80
references.pmid: 11907566
references.citation: N Engl J Med. 2001 Mar 15;344(11):783-92
references.pmid: 11248153
references.citation: Expert Rev Anticancer Ther. 2008 Dec;8(12):1883-90
references.pmid: 19046108
references.citation: Cancer Cell. 2004 Aug;6(2):117-27
references.pmid: 15324695
references.citation: Cancer. 2003 Jun 15;97(12):2972-7
references.pmid: 12784331
references.citation: J Clin Oncol. 2010 Jun 1;28(16):2698-704
references.pmid: 20421541
references.citation: J Clin Oncol. 2008 Jun 20;26(18):2999-3005
references.pmid: 18458039
references.citation: J Clin Oncol. 2008 Dec 1;26(34):5544-52
references.pmid: 18955454
references.citation: J Clin Oncol. 2005 Jun 20;23(18):4152-61
references.pmid: 15961763